Non-alcoholic steatohepatitis: diagnosis, management and challenges in clinical trials: an Indian perspective


  • Ena Lyn R. Ang IQVIA
  • Ma Cecilia M. Sison IQVIA, Makati, Philippines Institute of Digestive and Liver Diseases, St. Luke’s Medical Centre Global City, Taguig
  • Saket M. Ghaisas IQVIA, Mumbai, Maharashtra
  • Rashna C. Cama IQVIA, Mumbai, Maharashtra



Clinical trial, NAFLD, NASH


Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide and non-alcoholic steatohepatitis (NASH), its progressive form, is rapidly becoming the leading cause of end-stage liver disease and liver transplantation. There is a huge unmet need in the management of NAFLD and NASH. The key challenge is that NAFLD/NASH remains to be an under recognized disease despite its increasing prevalence, and early diagnosis is crucial to reduce the risk of progression and its consequent complications. In India, cases of NAFLD/NASH may go undetected due to lack of awareness and absence of a structured patient referral pathway. Efforts to increase patient and physician awareness along with standardization of local management guidelines for NAFLD and NASH can help improve patient care in India. Another major concern is the lack of approved NASH therapy; in order to address this issue, there has been a global surge in clinical trials. However, many countries, including India, have encountered challenges in the conduct of these trials related to patient recruitment and retention, lack of validated less invasive diagnostic tests, and the effect of placebo response on trial outcomes. Measures to improve the NAFLD and NASH clinical trial environment can help accelerate the approval and availability of better treatment options for NASH.



Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018;53:362-76.

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.

Goldberg D, Ditah IC, Saeian K, Lalehzari M, Aronsohn A, Gorospe EC, et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology. 2017;152:1090-9.

Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123-33.

Pati GK, Singh S. Nonalcoholic Fatty Liver Disease in South Asia. Euroasian J Hepato Gastroenterol. 2016;6:154-62.

Tandon N, Anjana RM, Mohan V, Kaur T, Afshin A, Ong K, et al. The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease Study 1990–2016. Lancet Glob Health. 2018;6:1352-62.

Luhar S, Mallinson PA, Clarke L, Kinra S. Trends in the socioeconomic patterning of overweight/obesity in India: a repeated cross-sectional study using nationally representative data. BMJ Open. 2018;8:e023935.

Younes R, Bugianesi E. NASH in Lean Individuals. Thieme Medical Publishers. Semin Liver Dis. 2019;39:86-95.

Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology. 2010;51:1593-602.

Duseja A. Nonalcoholic fatty liver disease in India – a lot done, yet more required! Indian J Gastroenterol. 2010;29:217-25.

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-57.

Marchesini G, Day CP, Dufour JF, Canbay A, Nobili V, Ratziu V, et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-402.

Duseja A, Singh SP, Saraswat VA, Acharya SK, Chawla YK, Chowdhury S, et al. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome—Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol. 2015;5:51-68.

Li Q, Dhyani M, Grajo JR, Sirlin C, Samir AE. Current status of imaging in nonalcoholic fatty liver disease. World J Hepatol. 2018;10:530.

Dulai P, Sirlin C, and Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. J Hepatol. 2016;65:1006-16.

Caussy C, Reeder S, Sirlin C, and Loomba R. Non-invasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials. Hepatology. 2018;68:763-72.

Cleveland E, Bandy A, VanWagner LB. Diagnostic challenges of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Clin Liver Dis. 2018;11:98.

Pathik, P, Ravindra S, Ajay C, Prasad B, Jatin P, Prabha S. Fibroscan versus simple noninvasive screening tools in predicting fibrosis in high-risk nonalcoholic fatty liver disease patients from Western India. Ann Gastroenterol. 2015;28:281.

Panackel, C, Jacob M, Francis J, Raja K, Sakpal M, Ganjoo N, et al. SAT-295-Diagnostic accuracy of non-invasive methods (NFS score and FIB-4) for detecting advanced fibrosis: A validation study of NFS score and FIB-4 in a cohort of South Indian patients with NAFLD. J Hepatol. 2019;70:768.

Iqbal U, Perumpail BJ, Akhtar D, Kim D, Ahmed A. The epidemiology, risk profiling and diagnostic challenges of nonalcoholic fatty liver disease. Medicines. 2019;6:41.

Fitzpatrick E, Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future. World J Gastroenterol. 2014;20:10851.

Cook N, Geier A, Schmid A, Hirschfield G, Kautz A, Schattenberg JM, Balp MM. The patient perspectives on future therapeutic options in NASH and patient needs. Front Med. 2019;6:61.

Said, A, Gagovic V, Malecki K, Givens ML, Nieto FJ. Primary care practitioners survey of non-alcoholic fatty liver disease. Ann Hepatol. 2013;12:758-65.

Polanco-Briceno, S, Glass D, Stuntz M, Caze A. Awareness of nonalcoholic steatohepatitis and associated practice patterns of primary care physicians and specialists. BMC Res Notes. 2016;9:1-12.

Arora, C, Sinha B, Ranjan P, Malhotra A. Non-alcoholic fatty liver disease: Problems in perception and solution. J Clin Diagn Res. 2018;12:1-5.

Alkhouri N, Lawitz E, Noureddin M. Looking into the crystal ball: Predicting the future challenges of fibrotic NASH treatment. Hepatol Commun. 2019;3:605-13.

Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: prevalence and impact on world health. Hepatology. 2016;64:19-22.

Connolly JJ, Ooka K, Lim JK. Future pharmacotherapy for non-alcoholic steatohepatitis (NASH): Review of Phase 2 and 3 trials. J Clin Transl Hepatol. 2018;6:264-75.

Rinella ME, Tacke F, Sanyal AJ, Anstee QM on behalf of the participants of the AASLD/EASL Workshop. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. J Hepatol. 2019;17:823-33.

Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L. Challenges and Opportunities in Drug and Biomarker Development for Nonalcoholic Steatohepatitis: Findings and Recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2015;61:1392-405.

Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13:643-54.

Sanyal A, Brunt E, Kleiner D, Kowdley K, Chalasani, N, Lavine J, et al. Endpoints and Clinical Trial Design for NASH. Hepatology. 2011;54:344-53.

Tanaka N, Kimura T, Fujimori N, Nagaya T, Komatsu M, Tanaka E. Current status, problems, and perspectives on non-alcoholic fatty liver disease research. World J Gastroenterol. 2019;25:163-77.

Liu, Xu and Wong. Serum Biomarkers for Nonalcoholic Fatty Liver Disease: Are We There Yet? Hepatology. 2017;65:8-11.

Rinella ME, Loomba R, Caldwell SH, Kowdley K, Charlton M, Tetri B, et al. Controversies in the Diagnosis and Management of NAFLD and NASH. Gastroenterol Hepatol. 2014;10:219-27.

Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander‐Tetri BA, et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018;68:361-71.

Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-85.

Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(23):7392-402.

Alkhouri N, McCullough AJ. Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. Gastroenterol Hepatol. 2012;8(10):661-8.

Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Front Gastroenterol. 2014;5:211-8.






Review Articles